SAREPTA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 128.8 USD | +1.08% |
|
+11.37% | +33.54% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 9,619 | 13,454 | 7,841 | 11,375 | 9,021 | 12,169 | - | - |
| Enterprise Value (EV) 1 | 9,176 | 12,944 | 6,822 | 10,930 | 8,582 | 10,974 | 9,577 | 7,834 |
| P/E ratio | -13.3 x | -24 x | -17.5 x | -16.1 x | -16.6 x | 56.5 x | 12.4 x | 13.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 25.3 x | 24.9 x | 11.2 x | 12.2 x | 7.26 x | 6.57 x | 4.2 x | 3.7 x |
| EV / Revenue | 24.1 x | 24 x | 9.72 x | 11.7 x | 6.9 x | 5.93 x | 3.3 x | 2.38 x |
| EV / EBITDA | -13.5 x | -24.1 x | -16.2 x | -22.1 x | -38.4 x | 69 x | 9.27 x | 5.55 x |
| EV / FCF | -17.8 x | 512 x | -14.2 x | -30.7 x | -14.9 x | 15.1 x | 19 x | - |
| FCF Yield | -5.62% | 0.2% | -7.06% | -3.26% | -6.72% | 6.64% | 5.27% | - |
| Price to Book | 11.9 x | 17.4 x | 8.45 x | 29.6 x | 10.5 x | 6.95 x | 4.12 x | 2.54 x |
| Nbr of stocks (in thousands) | 74,543 | 78,913 | 87,077 | 87,783 | 93,547 | 94,506 | - | - |
| Reference price 2 | 129.0 | 170.5 | 90.05 | 129.6 | 96.43 | 128.8 | 128.8 | 128.8 |
| Announcement Date | 26/02/20 | 01/03/21 | 01/03/22 | 28/02/23 | 28/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 380.8 | 540.1 | 701.9 | 933 | 1,243 | 1,852 | 2,898 | 3,293 |
| EBITDA 1 | -681.1 | -537.3 | -421.7 | -494.3 | -223.4 | 159 | 1,034 | 1,412 |
| EBIT 1 | -705.6 | -564.2 | -459.7 | -536.2 | -267.8 | 154.7 | 929.7 | 1,109 |
| Operating Margin | -185.27% | -104.46% | -65.5% | -57.47% | -21.54% | 8.36% | 32.08% | 33.67% |
| Earnings before Tax (EBT) 1 | -713.9 | -553.1 | -418.9 | -690 | -520.1 | 146.1 | 934.6 | 1,222 |
| Net income 1 | -715.1 | -554.1 | -418.8 | -703.5 | -536 | 213.6 | 1,004 | 1,065 |
| Net margin | -187.77% | -102.6% | -59.66% | -75.4% | -43.11% | 11.54% | 34.65% | 32.35% |
| EPS 2 | -9.710 | -7.110 | -5.150 | -8.030 | -5.800 | 2.280 | 10.40 | 9.826 |
| Free Cash Flow 1 | -516.1 | 25.26 | -481.7 | -356.2 | -577.1 | 728.7 | 504.5 | - |
| FCF margin | -135.52% | 4.68% | -68.62% | -38.17% | -46.42% | 39.35% | 17.41% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | 458.3% | 48.81% | - |
| FCF Conversion (Net income) | - | - | - | - | - | 341.09% | 50.25% | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 26/02/20 | 01/03/21 | 01/03/22 | 28/02/23 | 28/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 189.4 | 201.5 | 210.8 | 233.5 | 230.3 | 258.4 | 253.5 | 261.2 | 331.8 | 396.8 | 370.5 | 380.9 | 478.1 | 561.8 | 852.6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -34.46 | -105.8 | -86.88 | -211.1 | -131.4 | -106.8 | -138.1 | -133.5 | -20.84 | 24.62 | -18.33 | -25.95 | 59.64 | 118.8 | 369.9 |
| Operating Margin | -18.19% | -52.52% | -41.21% | -90.43% | -57.04% | -41.34% | -54.47% | -51.11% | -6.28% | 6.21% | -4.95% | -6.81% | 12.48% | 21.14% | 43.38% |
| Earnings before Tax (EBT) 1 | -47.91 | -121.9 | -104.1 | -228.1 | -256.4 | -101.3 | -512.7 | -14.58 | -33.17 | 40.37 | -16.02 | -27.36 | 52.55 | 109.6 | 372.9 |
| Net income 1 | -48.14 | -122 | -105.3 | -231.5 | -257.7 | -109.2 | -516.8 | -23.94 | -40.94 | 45.66 | -7.137 | -8.325 | 70.55 | 142.2 | 372.4 |
| Net margin | -25.42% | -60.55% | -49.95% | -99.14% | -111.93% | -42.27% | -203.85% | -9.16% | -12.34% | 11.51% | -1.93% | -2.19% | 14.76% | 25.3% | 43.68% |
| EPS 2 | -0.6000 | -1.420 | -1.200 | -2.650 | -2.940 | -1.240 | -5.860 | -0.2700 | -0.4600 | 0.4700 | -0.0150 | -0.0998 | 0.6496 | 1.378 | 3.760 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 03/11/21 | 01/03/22 | 04/05/22 | 02/08/22 | 02/11/22 | 28/02/23 | 02/05/23 | 02/08/23 | 01/11/23 | 28/02/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 443 | 510 | 1,019 | 445 | 438 | 1,196 | 2,592 | 4,336 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -516 | 25.3 | -482 | -356 | -577 | 729 | 505 | - |
| ROE (net income / shareholders' equity) | -77.3% | -70.1% | -49.6% | -40.9% | -86.2% | 28.7% | 48.6% | 48.4% |
| ROA (Net income/ Total Assets) | -41.3% | -23.1% | -13.7% | -8.55% | -1.86% | 8.05% | 9.28% | - |
| Assets 1 | 1,732 | 2,404 | 3,066 | 8,230 | 28,771 | 2,655 | 10,818 | - |
| Book Value Per Share 2 | 10.90 | 9.770 | 10.70 | 4.380 | 9.170 | 18.50 | 31.20 | 50.70 |
| Cash Flow per Share 2 | -6.200 | 1.380 | -5.450 | -3.720 | -5.420 | 2.870 | 14.10 | - |
| Capex 1 | 59.6 | 82.2 | 38.5 | 30.8 | 76.1 | 48.8 | 50.8 | 44.9 |
| Capex / Sales | 15.66% | 15.22% | 5.48% | 3.3% | 6.12% | 2.64% | 1.75% | 1.36% |
| Announcement Date | 26/02/20 | 01/03/21 | 01/03/22 | 28/02/23 | 28/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
128.8
USD
Average target price
164.5
USD
Spread / Average Target
+27.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +33.54% | 12.17B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| -24.71% | 8.24B |
- Stock Market
- Equities
- SRPT Stock
- Financials Sarepta Therapeutics, Inc.
